The US-government backed Phlow Corporation has closed a $20m series A financing, which the firm says will further aid its key initiatives directed towards accelerating US manufacturing for medicines at risk of shortage, including those useful in response to the COVID-19 pandemic.
“This injection of additional strategic capital will be used by Phlow to fund initiatives including building the company’s commercial business...




